戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ced neoplasia (colorectal cancer or advanced precancerous lesions).
2 t progression of ductal carcinoma in situ, a precancerous lesion.
3  or anal intraepithelial neoplasia (AIN) are precancerous lesions.
4 omozygous deletions in many cancer cells and precancerous lesions.
5 proliferation can be an initiating event for precancerous lesions.
6 characteristics similar to those reported in precancerous lesions.
7 f sustained protection against infection and precancerous lesions.
8 ectiveness of screening for and treatment of precancerous lesions.
9 ated cervical cytological abnormalities, and precancerous lesions.
10  epithelial cells and induce both benign and precancerous lesions.
11 has not been done to determine their role as precancerous lesions.
12 h the presence or absence of skin cancer and precancerous lesions.
13 al SCC and the effectiveness of treatment of precancerous lesions.
14 cts missed colorectal cancer (CRC) vs missed precancerous lesions.
15  common benign tumor that is suspected to be precancerous lesions.
16 ccination, early detection, and treatment of precancerous lesions.
17 d hallmark of cancer cells, is detectable in precancerous lesions.
18 ps through a series of increasingly abnormal precancerous lesions.
19  clinicopathological features in 166 ovarian precancerous lesions.
20 enesis, but have never been assessed in anal precancerous lesions.
21  neoplasia, and 13% sensitivity for advanced precancerous lesions.
22 sensitive detection of colorectal cancer and precancerous lesions.
23 essed in esophageal adenocarcinoma (EAC) and precancerous lesions.
24 xpression in somatic cells and is present in precancerous lesions.
25 accurate and reliable diagnosis of treatable precancerous lesions.
26  cancers (stage I/II, 66.4%) and 63 advanced precancerous lesions.
27 udying HNSCC initiation and progression from precancerous lesions.
28 ndary end point was sensitivity for advanced precancerous lesions.
29 y outcome was sensitivity to detect advanced precancerous lesions.
30  an emerging tool to pharmacologically treat precancerous lesions.
31 ibodies, and proteomic profiling for CGC and precancerous lesions.
32  of immune escape arise much earlier, within precancerous lesions.
33 r utility for detection of melanoma onset in precancerous lesions.
34 on, anogenital warts, and cervical cancer or precancerous lesions.
35 ich is universally accelerated in cancer and precancerous lesions.
36 elerate the development of H. pylori-induced precancerous lesions.
37 al predictor of the size and multiplicity of precancerous lesions.
38 nd rapid targeted therapy of colon cancer or precancerous lesions.
39 V testing for the identification of cervical precancerous lesions.
40 ays containing esophageal adenocarcinoma and precancerous lesions.
41 o enhance the detection of early cancers and precancerous lesions.
42 nd may forecast a similar effect on cervical precancerous lesions.
43 associated with an increased risk of gastric precancerous lesions.
44 ntiation following tissue damage, leading to precancerous lesions.
45 ith men (MSM) without history of anal cancer/precancerous lesions.
46 vated (phosphorylated at T68) in cancers and precancerous lesions.
47 the maintenance of cervical cancers and most precancerous lesions.
48  adenocarcinoma, squamous cell carcinoma and precancerous lesions.
49 cervical HPV 16/18 infections and associated precancerous lesions.
50 ancerous tissues including tissue containing precancerous lesions.
51 o accelerate the development of hyperplastic precancerous lesions.
52 ma models, as well as evidence from clinical precancerous lesions; 2) suggest that OIS is targetable;
53  of samples from 94 East Asian patients with precancerous lesions [25 with atypical adenomatous hyper
54  98 had colorectal cancer, 2144 had advanced precancerous lesions, 6973 had nonadvanced adenomas, and
55                                          For precancerous lesions, 9 studies were included that analy
56 s the ability of the test to detect advanced precancerous lesions (advanced adenoma or advanced serra
57 olorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serra
58 ls of selected bacterial species and gastric precancerous lesions, although an elevated but non-signi
59 dontal disease-related pathogens and gastric precancerous lesions among those with higher versus lowe
60 qHPV vaccination against high-grade cervical precancerous lesions, among women vaccinated with 1, 2,
61  to determine whether KRAS(G12D) would block precancerous lesion and tumor formation in follicles of
62 esophagus, stomach, and colon in people with precancerous lesions and a high risk of developing these
63 ve cervical cancer, and an increased risk of precancerous lesions and a lower degree of participation
64 ted that CUL4A may be a prognostic marker of precancerous lesions and a potential therapeutic target
65 nd calibrated it to US epidemiologic data on precancerous lesions and cancer.
66 ubsequent HPV acquisition and progression to precancerous lesions and cancers.
67 baseline data on the prevalence and types of precancerous lesions and early-stage cancer among partic
68 ntified a significant proportion of PWH with precancerous lesions and early-stage cancer.
69  CA9 expression in esophageal cancers and in precancerous lesions and explored the association of CA9
70 prostate gland susceptibility to adult-onset precancerous lesions and hormonal carcinogenesis.
71 tion of mutations that are seen within later precancerous lesions and in established malignancy can a
72 ion of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of pri
73 mined the expression of Claudin-2 in EAC and precancerous lesions and its association with VDR and TG
74 nd sensitive for the detection of high-grade precancerous lesions and may be used in primary cervical
75 iency leads to persistent DNA damage in both precancerous lesions and primary tumors.
76 l of cutaneous carcinogenesis that manifests precancerous lesions and SCCs resembling human disease.
77 e quantification of sensitivity for advanced precancerous lesions and specificity for nonneoplastic f
78 iminate with a very high performance between precancerous lesions and T1a carcinoma (sensitivity, 100
79 is significantly affected in the presence of precancerous lesions and T1a carcinoma.
80 between periodontal disease and the risk for precancerous lesions and tumors generating a hypothesis
81 pregulated in mutant KRAS-driven metaplasia, precancerous lesions, and classical PDAC.
82 rogression, including delayed development of precancerous lesions, and decreased tumor growth and met
83 opsies from normal esophagus, early and late precancerous lesions, and esophageal cancers to decipher
84  mitotic-age increases in normal tissues and precancerous lesions, and hence for developing cancer-ri
85 igin fraction in each of 15 cancer-types, in precancerous lesions, and in normal tissues exposed to m
86 infection for high-risk types, prevalence of precancerous lesions, and incidence of cancer.
87 is of H. pylori infection, detecting gastric precancerous lesions, and other specific clinical applic
88 ing of mutational signatures in human cells, precancerous lesions, and primary or metastatic tumors a
89 s were employed: 1) tumor (non-specific); 2) precancerous lesions; and 3) any oral soft tissue lesion
90  (AOR, 1.93; 95% CI, 1.15-3.26) and lifetime precancerous lesions (AOR, 3.85; 95% CI, 1.73-8.57).
91                                     Advanced precancerous lesion (APL) sensitivity was a key determin
92 options for low-grade endometrial cancer and precancerous lesions are a critical unmet need for women
93          Most squamous cell anal cancers and precancerous lesions are attributed to human papillomavi
94 ation and endoscopic surveillance of gastric precancerous lesions are strategies to reduce gastric ca
95 n in 170 cases of esophageal cancer (EC) and precancerous lesions, as well as 20 cases of EC series s
96                              Metaplasia is a precancerous lesion associated with an increased risk fo
97 n of infection with HPV 16/18 and associated precancerous lesions at the cervix.
98 s of esophageal adenocarcinoma (EAC) and its precancerous lesion, Barrett's esophagus (BE).
99 ology necessitates further classification of precancerous lesions based on positive interpretations.
100 itivities for colorectal cancer and advanced precancerous lesions between the multitarget stool DNA t
101 ta-carotene has established efficacy in oral precancerous lesions but has no effect or slightly worse
102  integrity and serves as a cancer barrier in precancerous lesions but paradoxically may promote cance
103 which developmental chemical exposure causes precancerous lesions by altering cell fate.
104 cedure to discriminate between malignant and precancerous lesions by measuring the characteristics of
105 ore, both stem and non-stem cells in mammary precancerous lesions can contribute to the eventual canc
106  women worldwide, and early detection of its precancerous lesions can decrease mortality.
107 ention) and screening and early treatment of precancerous lesions caused by HPV infections (secondary
108 reported the underrepresentation of cervical precancerous lesions caused by human papillomavirus (HPV
109 e show that CXCL10 is produced by pancreatic precancerous lesion cells in response to IFNy signaling
110 nd who do not have a history of a high-grade precancerous lesion (cervical intraepithelial neoplasia
111 sistent with the in vitro findings, in human precancerous lesions, CUL4A expression gradually increas
112 the pancreatic phenotype evolved to resemble precancerous lesions, demonstrating that loss of Lkb1 wa
113                      We show that pancreatic precancerous lesions develop into distinct 3D morphologi
114 ect of stomach function that is disrupted in precancerous lesions (e.g. metaplasias, chronic atrophy)
115 d in future diagnostics for the detection of precancerous lesions, e.g. the identification of high gr
116  Fbxw7 and Pten resulted in the formation of precancerous lesions (endometrioid intraepithelial neopl
117 nt vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic pote
118 ost human trials have been conducted against precancerous lesions for SCC.
119 ys significantly reduced mutant KRAS-induced precancerous lesion formation.
120 lastic aberrant crypt foci (ACF), a putative precancerous lesion found in the colon, exhibiting a ser
121 ent mechanisms of neoplastic control prevent precancerous lesions from becoming fully malignant, iden
122 e in distinguishing individuals with CGC and precancerous lesions from healthy controls (AUC = 0.931
123 phagitis in this patient were similar to the precancerous lesions from high-risk areas for esophageal
124 risk factors and potential for screening for precancerous lesions had heterogeneous trends and the gr
125 pillomavirus (hrHPV) detects more high-grade precancerous lesions, has a higher negative predictive v
126 yclin E in esophageal adenocarcinoma and its precancerous lesion have not been well studied.
127  minimally deleted regions and their role in precancerous lesions have not been well characterized.
128 can lead to colon cancer that is preceded by precancerous lesions having submucosal inflammation and
129 tal neoplasia (colorectal cancer or advanced precancerous lesions) identified on colonoscopy had a ne
130 tivated in some actinic keratoses, the major precancerous lesion in human skin.
131 identified in 109 participants, including 60 precancerous lesions in 35 patients (3.0%), 9 early-stag
132 ed oral pathogens is associated with gastric precancerous lesions in a cross-sectional study.
133                                Comparison of precancerous lesions in donor woodchucks versus recipien
134  frequently detected in normal-to-high-grade precancerous lesions in Estonia.
135 nogenesis and has been shown to regress oral precancerous lesions in humans.
136 nfirmed multiple (up to eight) distinct ERG+ precancerous lesions in infected cases.
137       Here, we show that VHL inactivation in precancerous lesions in kidneys from patients with VHL d
138 ertain, despite the diagnosis and removal of precancerous lesions in many persons who undergo screeni
139 Tgfbr1 signaling promotes the development of precancerous lesions in mice.
140 epithelia, LSS imaging can be used to detect precancerous lesions in optically accessible organs.
141 lecular events that drive the development of precancerous lesions in the bronchial epithelium, which
142 liver toxicity and an increased incidence of precancerous lesions in the colon of HZ mice.
143  demonstrated the ability to detect advanced precancerous lesions in the colorectum, esophagus, and s
144 o reveal that ATM is activated in pancreatic precancerous lesions in the context of DNA damage and ce
145 e acetate promotes regression of cancers and precancerous lesions in the female lower reproductive tr
146 tiffens the extracellular matrix and induces precancerous lesions in the mammary tissues.
147 ompare the incidence, frequency, and size of precancerous lesions in the pancreas.
148 esolving the phylogenetic relationship among precancerous lesions in ulcerative colitis and for traci
149 acterial prostatitis is associated with ERG+ precancerous lesions in unique cases with active bacteri
150  E7 in maintaining HPV-associated tumors and precancerous lesions in vivo, we generated Bi-L E7 trans
151 V vaccine (qHPV) reduces risk of anal cancer/precancerous lesions in young men who have sex with men
152                                     Advanced precancerous lesions included one or more adenomas or se
153 nhanced ERK and JNK-induced proliferation in precancerous lesions, indicating a potential role as a b
154 n aberrant expression of MUC4 is reported in precancerous lesions, indicating its early involvement i
155 areas for esophageal squamous cancer and the precancerous lesions induced in rats by N-methyl-N-nitro
156 otein-positive (WAP+) cell subset in mammary precancerous lesions initiated by the Wnt1 oncogene.
157                                     Studying precancerous lesions is essential for improving early de
158 normal neighbors on malignant progression of precancerous lesions is not well understood.
159                                          The precancerous lesion known as Barrett's oesophagus can ev
160  Here, we performed single-cell profiling of precancerous lesions, localized and metastatic GACs, ide
161 ationships among multiple oral cancerous and precancerous lesions (MOCP), we analysed 100 lesions fro
162                     Treatment modalities for precancerous lesions need to be improved.
163 tal neoplasia (colorectal cancer or advanced precancerous lesions), negative predictive value for adv
164 altered hepatic foci, which are the earliest precancerous lesions observed in the liver of woodchuck
165 al supplementation of green tea extract on a precancerous lesion of oral cavity.
166                 These are characteristics of precancerous lesions of bile duct.
167                           Paradoxically, the precancerous lesions of EL-Kras/Tgfbr1(+/-) mice were co
168 ise and challenge of studying STIC and other precancerous lesions of HGSC.
169 enescent cells comprise a major component of precancerous lesions of skin, oral mucosa, nasopharynx,
170 scopy could risk-stratify patients harboring precancerous lesions of the colon, using an optically me
171                   Actinic keratosis (AK) are precancerous lesions of the skin which may progress to i
172                Thus, remarkably, features of precancerous lesions often attributed to defects in cell
173 elops through a stochastic mechanism whereby precancerous lesions on occasion progress to multifocal
174 sion procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new hu
175 beta nonresponsive stromal cells resulted in precancerous lesions, only the mixture of TGF-beta respo
176 crucial task to ensure accurate detection of precancerous lesions or cancer; this is true for both gy
177           PKCY Il22(-/-)mice did not develop precancerous lesions or pancreatic tumors.
178  tumor (OR = 4.57, 95% CI: 2.25 to 9.30) and precancerous lesions (OR = 1.55, 95% CI: 1.06 to 2.27).
179 ns was significantly associated with gastric precancerous lesions (OR = 2.51, 1.13-5.56) among those
180  colonoscopy (no colorectal cancer, advanced precancerous lesions, or nonadvanced precancerous lesion
181 associated with an increased risk of CGC and precancerous lesions (P for trend < 0.05).
182 colorectal cancer (P<0.001) and for advanced precancerous lesions (P<0.001) but had lower specificity
183 ed from 116 esophageal adenocarcinoma and 26 precancerous lesion patients using Affymetrix SNP 6.0 ar
184 NA methylation occurs within promoter before precancerous lesion plays a pivotal role that could help
185  track tumour burden and ctDNA shedding from precancerous lesions post-treatment without requiring ma
186                                        Since precancerous lesions precede intestinal-type gastric can
187 ced neoplasia (colorectal cancer or advanced precancerous lesions) relative to screening colonoscopy.
188  cancer detection, but detection of advanced precancerous lesions remains a challenge, and ongoing ef
189                                     In early precancerous lesions, S100PBP is translocated to the cyt
190 s do not develop many of the novel tumors or precancerous lesions seen in Rb+-;p53-- compound mutants
191  the earliest molecular landscape of ovarian precancerous lesions, serving as the foundation for futu
192 nd 23.3% (95% CI, 21.5 to 25.2) for advanced precancerous lesions; specificity was 94.8% (95% CI, 94.
193 inactivation increases dramatically in early precancerous lesion stage while CNAs and APOBEC mutagene
194 mal cells usually have to progress through a precancerous lesion state before becoming a full-blown t
195                                 Detection of precancerous lesions such as CR adenoma is a key to redu
196            Our findings suggest that certain precancerous lesions, such as Barrett's, initiate not fr
197 nsitivity for colorectal cancer and advanced precancerous lesions than FIT but also showed lower spec
198 ell carcinoma in situ (SCCIS) is a prevalent precancerous lesion that can progress to cutaneous squam
199              IPMT is a dysplastic and likely precancerous lesion that is frequently diagnosed as chro
200 nomas in the large intestine, similar to the precancerous lesions that develop in patients with FAP.
201 ate carcinogenesis can develop a spectrum of precancerous lesions that resemble human prostatic intra
202 t cuSCC arise in association with a distinct precancerous lesion, the actinic keratosis (AK).
203        However, due to limited data on early precancerous lesions, the timing of these transitions an
204 rocedures that can detect disease and remove precancerous lesions, there is a need for a model that e
205 e in the endoscopic detection and removal of precancerous lesions, thereby deferring or avoiding surg
206  event that can accelerate the transition of precancerous lesions to cancer.
207  nonimmune cells during early progression of precancerous lesions to lung adenocarcinomas and shed li
208                           The progression of precancerous lesions to malignancy is often accompanied
209      It may be used to diagnose malignant or precancerous lesions, to delineate the margins for tumor
210                 The sensitivity for advanced precancerous lesions was 12.5% (321/2567; 95% CI, 11.3%-
211  75.3 to 94.1), and sensitivity for advanced precancerous lesions was 13.2% (95% CI, 11.3 to 15.3).
212               Sensitivity to detect advanced precancerous lesions was 23% with a refined version of t
213                             The frequency of precancerous lesions was 4-fold lower in haploinsufficie
214       The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8
215                     Sensitivity for advanced precancerous lesions was 43.4% (95% CI, 41.3 to 45.6), a
216 d with diethylnitrosamine, the occurrence of precancerous lesions was enhanced compared with that in
217  non-significant odds ratio (OR) for gastric precancerous lesions was observed in relation to increas
218                       The development of the precancerous lesions was significantly reversed by the a
219 re limited to settings in which treatment of precancerous lesions was withheld or inadequate.
220 dvanced precancerous lesions, or nonadvanced precancerous lesions) was 89.9% (95% CI, 89.0 to 90.7).
221 le early detection of pancreatic cancer from precancerous lesions, we analyze proteins and glycoprote
222     Our previous works suggest that although precancerous lesions were found in Pten heterozygous mic
223                   A total of 800 adults with precancerous lesions were randomized to anti-H pylori tr
224 a marker of HPV infection in both benign and precancerous lesions, whereas the approximately 10% of t
225 ssociated with esophageal adenocarcinoma and precancerous lesions, which implies that Bmi-1 plays an
226 se stem cells develop the characteristics of precancerous lesions while retaining the self-renewal ca
227  of developing pancreatic cancer to identify precancerous lesions while they are amenable to cure.
228  shown to detect both colorectal cancers and precancerous lesions with high accuracy.
229 s with squamous cell T1a carcinoma, ten with precancerous lesions with hyperkeratosis, and ten subjec

 
Page Top